Type of Spiritual Experience
A description of the experience
Mirabegron (trade name Myrbetriq meer-BET-trick in the US and Betmiga in Europe) is a drug for the treatment of overactive bladder. It was developed by Astellas Pharma and was approved in the United States in July 2012.
Mirabegron activates the β3 adrenergic receptor in the detrusor muscle in the bladder, which leads to muscle relaxation and an increase in bladder capacity.
Most common Myrbetriq side effects from eHealthme
- Drug ineffective - (1,521 reports)
- High blood pressure - (635 reports)
- Headache - (418 reports)
- Constipation - (284 reports)
- Dizziness - (269 reports)
- Urination - excessive at night - (218 reports)
- Fatigue - (214 reports)
- Urinary tract infection - (209 reports)
- Rashes - (206 reports)
- Diarrhea - (203 reports)
On Jan, 08, 2017 6,305 people reported to have side effects when taking Myrbetriq.
Among them, 24 people (0.38%) have Death
On Feb, 07, 2017 6,305 people reported to have side effects when taking Myrbetriq. Among them, 22 people (0.35%) have Hallucination
On Feb, 07, 2017 6,305 people reported to have side effects when taking Myrbetriq. Among them, 1 person (0.02%) has Hallucination, Auditory